When hepatocellular carcinoma (HCC) is centrally adherent to major vessels, radiotherapy administered after surgery improves outcomes even in the setting of negative surgical margins, according to a ...

Among patients treated without adjuvant radiotherapy, patients with non-low-risk disease experienced low rates of isolated pelvic (2.1%) and vaginal (6.7%) recurrences. 91% of vaginal recurrences were ...

Please provide your email address to receive an email when new articles are posted on . SAN ANTONIO — Treatment de-escalation may be possible for patients with breast cancer who respond well to ...

Please provide your email address to receive an email when new articles are posted on . Patients with advanced muscle-invasive bladder cancer had lower risk for local recurrence with adjuvant ...

The locoregional recurrence-free survival rate at 2 years was significantly higher for patients treated with chemotherapy plus RT versus those treated with chemotherapy alone. Adding adjuvant ...

p16 Protein Expression and Human Papillomavirus Status As Prognostic Biomarkers of Nonoropharyngeal Head and Neck Squamous Cell Carcinoma We evaluated 1,107 patients with pN1 prostate cancer treated ...

The Profile for the Omission of Local Adjuvant Radiation (POLAR) biomarker, a 16-gene molecular signature, can help predict locoregional recurrence in patients with ER-positive early breast cancer ...

Pathologic Complete Response As a Potential Surrogate for the Clinical Outcome in Patients With Breast Cancer After Neoadjuvant Therapy: A Meta-Regression of 29 Randomized Prospective Studies The ...

Results from the NRG Oncology GOG-0263 phase III clinical trial testing the addition of cisplatin-based chemotherapy to adjuvant radiotherapy following radical hysterectomy and lymphadenectomy for ...

Trastuzumab deruxtecan continues to demonstrate superior safety and efficacy compared with trastuzumab emtansine in patients with high-risk, HER2-positive early breast cancer who have residual ...

New findings on radiation plus adjuvant chemotherapy in patients with intermediate-risk cervical cancer seem to spell the end for the dual therapy in this group. Results from a phase 3 clinical trial ...